A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies
Constellation Pharmaceuticals
Constellation Pharmaceuticals
Ohio State University Comprehensive Cancer Center
M.D. Anderson Cancer Center
AbbVie
Icahn School of Medicine at Mount Sinai
Vanderbilt-Ingram Cancer Center
M.D. Anderson Cancer Center
Incyte Corporation
Hoffmann-La Roche
Gilead Sciences
Novartis
M.D. Anderson Cancer Center
Incyte Corporation
Incyte Corporation
Children's Oncology Group
Incyte Corporation